Meeting
2022 ASCO Annual Meeting
Pyrotinib monotherapy or pyrotinib in combination with capecitabine could significantly prolong progression-free survival and overall survival in patients with HER2-positive metastatic breast cancer.
Authors
Xiuwen Guan
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Xiuwen Guan , Fei Ma , Qiao Li , Shanshan Chen , Bo Lan , Ying Fan , Jiayu Wang , Yang Luo , Ruigang Cai , Pin Zhang , Qing Li , Binghe Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT01937689,NCT02361112,NCT02422199,NCT03080805
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1034)
DOI
10.1200/JCO.2022.40.16_suppl.1034
Abstract #
1034
Poster Bd #
412
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2-positive metastatic breast cancer patients: A phase I clinical trial.
First Author: Fei Ma
Poster
2021 ASCO Annual Meeting
Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study.
First Author: Min Yan
Poster
2020 ASCO Virtual Scientific Program
Pyrotinib plus capecitabine for HER2-positive, trastuzumab-resistant metastatic breast cancer: A pooled analysis of three randomized controlled trials.
First Author: Zefei Jiang
Poster
2011 Breast Cancer Symposium
Correlation of efficacy between rash and lapatinib/capecitabine therapy in Japanese HER2-positive metastatic breast cancer patients.
First Author: S. E. Nagai